BMS-813160 is the first dual CCR2/CCR5 antagonist to enter clinical development for cardiovascular.
References:
[1]. Norman P. et al. A dual CCR2/CCR5 chemokine antagonist, BMS-813160 Evaluation of WO2011046916. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
















